Core Viewpoint - The company, Entropy Technology (301330.SZ), is pursuing a strategy that combines both organic growth and external development through acquisitions [1] Group 1: Acquisition Strategy - The acquisition of Longzhiyuan marks the company's first acquisition project since its listing [1] - The company plans to continue seeking other projects that can empower its growth through investments or acquisitions [1] Group 2: Shareholding and Financial Impact - On October 17, the company announced the signing of a "Letter of Intent for Acquisition" with Longzhiyuan, with the shareholding change expected to be completed by the end of November [1] - Upon completion of the shareholding change, Entropy Technology will hold 55% of Longzhiyuan's shares and will consolidate its financial statements [1]

Core Viewpoint - IDT INT'L (00167) and joint offerors Horizon Heights Limited and Hong Kong Hongli Technology Co., Ltd. have completed the acquisition of approximately 312.4 million shares, representing about 72.1% of the company's issued share capital, for a total consideration of approximately HKD 185.6 million, equating to HKD 0.5941 per share [1] Summary by Relevant Sections - Acquisition Details - The joint offerors completed the acquisition on October 30, 2025, acquiring around 312.4 million shares [1] - The total consideration for the acquisition was approximately HKD 185.6 million, translating to HKD 0.5941 per share [1] - Mandatory Cash Offer - Following the acquisition, the joint offerors are required to make a mandatory unconditional cash offer for all issued shares at HKD 0.5941 per share [1] - This offer represents a discount of approximately 68.90% compared to the last trading price of HKD 1.91 per share on the Hong Kong Stock Exchange [1] - Resumption of Trading - The company has applied for the resumption of trading of its shares, effective from 9:00 AM on November 18, 2025 [1]

Core Viewpoint - Jamf Holding Corp. is under investigation for potential breaches of fiduciary duties by its board of directors in relation to a proposed take-private sale at $13.05 per share, which may be considered an unfairly low price for shareholders [1][3]. Group 1: Investigation Details - The investigation is led by Bleichmar Fonti & Auld LLP, focusing on whether Jamf's board and Vista Equity Partners have acted in the best interests of shareholders regarding the acquisition by Francisco Partners Management, L.P. [5][3]. - Jamf's board did not form an independent special committee to assess the acquisition, raising concerns about conflicts of interest, particularly since Vista owns 34.4% of Jamf's stock and has the right to appoint four board members [4][3]. Group 2: Shareholder Implications - Current shareholders of Jamf are encouraged to seek additional information and may have legal options available to them regarding the proposed transaction [2][6]. - The acquisition is contingent upon a stockholder vote, but Vista's participation in that vote has not been excluded, which could further complicate the situation for shareholders [4][3].

Core Viewpoint - Avadel Pharmaceuticals has received an unsolicited acquisition proposal from H. Lundbeck A/S at a price of $23.00 per share, which includes $21.00 in cash and potential additional cash payments based on future sales of LUMRYZ™ and valiloxybate [1][7]. Group 1: Acquisition Proposal Details - The Lundbeck proposal includes a cash payment of $21.00 per share and a contingent value right (CVR) that could provide an additional $1.00 per share if certain sales milestones are met by specified dates [1]. - The total value of Lundbeck's proposal is approximately $2.25 billion [7]. - Avadel's board has determined that the Lundbeck proposal may be considered a "superior proposal" compared to its existing agreement with Alkermes, which offers $20.00 per share, consisting of $18.50 in cash and a CVR of $1.50 [2][7]. Group 2: Current Status and Implications - Avadel's board is currently reviewing the Lundbeck proposal and has been authorized to provide information and engage in discussions with Lundbeck, but cannot terminate the existing agreement with Alkermes [3][7]. - Alkermes has stated that it is considering its options following Lundbeck's proposal and emphasized that Avadel must first negotiate with Alkermes before accepting any alternative offers [7][9]. - Avadel shareholders are not required to take any action at this time as discussions are ongoing [6]. Group 3: Strategic Context - Lundbeck is shifting its operational model towards a partnership approach, focusing on higher-value innovative drug products, which aligns with its recent strategic adjustments [10]. - The competitive landscape is highlighted by a recent bidding war involving another biotech company, Metsera, indicating a trend of increased acquisition activity in the sector [10].

Core Viewpoint - Heidrick & Struggles International, Inc. is facing scrutiny regarding the fairness of its proposed buyout at $59.00 per share, which may not adequately reflect the company's strong financial performance [1][2]. Financial Performance - On November 3, 2025, Heidrick reported earnings per share of $0.83, exceeding the estimated $0.76, and achieved revenue of approximately $322.8 million, surpassing the estimated $304.9 million, indicating a robust financial position [2]. Stock Performance - HSII's current stock price is $58.63, slightly below the proposed buyout price of $59.00 per share, with a market capitalization of approximately $1.22 billion. The stock has shown a stable growth trajectory over the past year, trading between a high of $58.85 and a low of $36.87 [3]. Investor Interest - The trading volume for HSII today is 212,208 shares, indicating active investor interest. Shareholders who believe the buyout price undervalues the company are encouraged to reach out to Kaskela Law LLC, which specializes in representing investors in securities fraud and corporate governance [4].

Core Viewpoint - Jamf Holding Corp. is under investigation for potential breaches of fiduciary duties by its board of directors in relation to a proposed take-private sale at a price of $13.05 per share, which may be considered unfair to shareholders [1][3]. Group 1: Investigation Details - The investigation is led by Bleichmar Fonti & Auld LLP, focusing on whether Jamf's board and Vista Equity Partners have acted in the best interests of shareholders regarding the acquisition by Francisco Partners Management, L.P. [5][3]. - Jamf's board did not form an independent special committee to assess the acquisition, raising concerns about conflicts of interest, especially since Vista owns 34.4% of Jamf's stock and has the right to appoint four board members [4][3]. Group 2: Shareholder Implications - Current shareholders of Jamf are encouraged to seek additional information and may have legal options available to them regarding the proposed transaction [2][6]. - The acquisition deal is contingent upon a shareholder vote, but Vista's involvement in the vote has not been excluded, which could influence the outcome [4][3].

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 400 points, down 0.91% to 46,906.05, NASDAQ down 1.59% to 23,456.33, and S&P 500 down 1.17% to 6,772.04 [1] - Consumer staples shares increased by 0.5%, while information technology stocks decreased by 1.8% [1] Pfizer Inc. Performance - Pfizer reported better-than-expected third-quarter earnings of 87 cents, compared to $1.06 a year ago, surpassing the consensus estimate of 63 cents [2] - Third-quarter sales fell 6% year-over-year to $16.65 billion, slightly above the consensus of $16.59 billion, reflecting an operational decline of 7% [2] - Pfizer raised its fiscal 2025 adjusted earnings guidance from $2.90-$3.10 per share to $3.00-$3.15, compared to the consensus of $3.04 [3] Commodity Market - Oil prices decreased by 1.2% to $60.34, gold fell by 1.8% to $3,943.90, silver dropped 2.6% to $46.780, and copper also fell 2.6% to $4.9355 [6] European Market Performance - European shares were lower, with the eurozone's STOXX 600 declining 0.7%, Spain's IBEX 35 down 0.5%, London's FTSE 100 down 0.4%, Germany's DAX 40 down 1.2%, and France's CAC 40 down 0.9% [7] Asian Market Performance - Asian markets closed lower, with Japan's Nikkei 225 down 1.74%, Hong Kong's Hang Seng down 0.79%, China's Shanghai Composite down 0.41%, and India's BSE Sensex down 0.62% [8] Notable Stock Movements - Evoke Pharma shares surged 135% to $10.74 after announcing an acquisition agreement with QOL Medical [9] - Denny's Corporation shares rose 50% to $6.16 following an acquisition announcement valued at approximately $620 million [9] - Prelude Therapeutics shares dropped 56% to $1.7601 after signing an acquisition agreement with Incyte [9] - JELD-WEN Holding shares fell 38% to $2.61 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [9]

Company Performance - Pfizer Inc. reported better-than-expected earnings for Q3 2025, with adjusted earnings of 87 cents, surpassing the consensus estimate of 63 cents, although down from $1.06 a year ago [2] - Pfizer's Q3 sales fell 6% year over year to $16.65 billion, slightly beating the consensus of $16.59 billion, reflecting an operational decline of 7% [2] - Pfizer raised its fiscal 2025 adjusted earnings guidance from a range of $2.90-$3.10 per share to $3.00-$3.15, compared to the consensus of $3.04 [3] Market Movements - Evoke Pharma, Inc. shares surged 135% to $10.74 after announcing a definitive agreement to be acquired by QOL Medical [9] - Denny's Corporation shares increased by 50% to $6.16 following the announcement of an all-cash acquisition deal valued at approximately $620 million, or $6.25 per share [9] - Prelude Therapeutics Incorporated shares dropped 56% to $1.7601 after signing an agreement for Incyte to acquire its JAK2V617F JH2 inhibitor program [9] - JELD-WEN Holding, Inc. shares fell 38% to $2.61 after reporting worse-than-expected Q3 financial results and cutting its FY25 guidance below estimates [9]

Investment Rating - The investment rating for Luoyang Molybdenum (603993) is maintained as "Buy" [2][6]. Core Insights - The company's Q3 2025 performance exceeded expectations, with total revenue of 145.5 billion yuan (down 6.0% year-on-year) and a net profit of 14.28 billion yuan (up 72.6% year-on-year) primarily due to rising copper prices and increased copper production and sales [6]. - The company plans to invest in the KFM Phase II project, expected to commence production in 2027, which will add an average of 100,000 tons of copper per year upon completion [6]. - The acquisition of Lumina Gold Company enhances the company's portfolio, adding a gold project with significant resources located in Ecuador [6]. - The profit forecasts for 2025-2027 have been revised upwards due to rising copper prices and production exceeding initial plans, with projected net profits of 19.56 billion, 22.80 billion, and 25.90 billion yuan respectively [6]. Financial Data and Profit Forecast - Total revenue for 2025 is estimated at 216.1 billion yuan, with a year-on-year growth rate of 1.4% [5]. - The projected net profit for 2025 is 19.56 billion yuan, reflecting a significant increase of 44.5% year-on-year [5]. - The company's gross margin is expected to be 19.8% in 2025, with a return on equity (ROE) of 22.6% [5].

Core Viewpoint - Kaskela Law LLC is investigating the proposed buyout of Integral Ad Science (IAS) by Novacap to assess the fairness of the transaction for the company's investors [1][2]. Group 1: Transaction Details - IAS announced an agreement to be acquired by Novacap at a price of $10.30 per share in cash on September 24, 2025 [1]. - Following the transaction's closing, IAS shareholders will be cashed out and will not benefit from any future financial upside [1]. Group 2: Concerns Raised - The investigation has identified significant conflicts of interest in the transaction, suggesting that the sales process and consideration may be unfair to investors [2]. - Analysts had set price targets for IAS shares above $13.50 at the time of the announcement, indicating that the buyout price may be undervalued [2]. Group 3: Investor Actions - IAS shareholders who believe the buyout price is too low are encouraged to contact Kaskela Law LLC to discuss their legal rights and options regarding the transaction [3]. - Kaskela Law LLC has a track record of recovering over $500 million for investors since 2020 [3].